1969), suggesting that its insulin-stimulating effect is mediated through one or more of the intestinal insulin-stimulating hormones. The degree of hyperglycaemia after ingestion of fructose or galactose is similar and small; however, ingestion of galactose elevates circulating concentrations of gastric inhibitory polypeptide, whereas fructose does not (Sykes et al., 1979).
In 1938 Feyrter postulated the existence of a 'diffuse endocrine gland'. Using conventional histology he noted the presence of many poorly stained ('clear') cells, diffusely distributed in various tissues including the gastrointestinal tract, but for many years this concept remained a mere speculation.
The discovery of numerous peptide hormones from the gastrointestinal tract and the observation that these are produced by specialized endocrine 'clear' cells scattered among the other epithelial non-endocrine cells reinforced Feyrter's early concept.
The existence of a 'diffuse endocrine system' distinct from the classical 'glandular endocrine system' is now well recognized.
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Glandular endocrine systems consist of a compact mass of cells which makes extirpation possible. Also the hormone concentration in efferent blood can be measured after a specific stimuli. In contrast the diffuse endocrine systems consist of scattered single cells and nerve fibres throughout the body. This makes extirpation impossible. Although there is a synchronized response to stimuli, the local response cannot yet be measured.
Brain and gut peptides
In 1931 von Euler & Gaddum extracted a similar peptide from both the brain and the gut. But the full realization that there are many peptides common to both sites did not come for more than 40 years after the discovery that somatostatin, originally thought to be a hypothalamic peptide, was present also in the gut (Arimura et al., 1975) . The list of 'neuropeptides' has increased rapidly and now includes: vasoactive the precise quantity present in blood and tissue.
Individual peptides
Peptide hormones acting via the circulation. Eight peptide hormones extracted from the gut are known to act via the circulation. Their distribution, cellular origin and biochemical characteristics are listed in Table 1 . Further details are given in the accompanying paper (Bloom & Polak, 1980) . Neuropeptides. The majority of the 'neuropeptides' are extensively distributed, being found not only within the gut, but also in many other organs, e.g. lung, genito-urinary tract, skin and salivary glands (Polak & Bloom, 1 9 7 9~) .
The spectrum of actions of these peptides is wide, and a specific action is probably dependent on their anatomical distribution. The effect of a neuropeptide seems to be only local or 'paracrine'; that is, it is confined to the site of release. Thus the presence of some of the neuropeptides in the circulation may merely reflect an overtlow phenomenon.
Vasoactive intestinal polypeptide. Vasoactive intestinal polypeptide is a 28-amino acid peptide originally extracted in large quantities from the gut and later found to be present, also in large quantities, in the brain. It has a wide spectrum of actions including muscle relaxation, vasodilation and intestinal secretion (Said, 1978) . In the gut it is found from the oesophagus to the rectum and is localized by immunocytochemistry mainly in the innervation of the gut wall. Fine varicose nerve fibres are seen in both plexi as well as in the two muscle layers the mucosa and the submucosa. These nerve fibres originate from intrinsic cell bodies, which can occasionally be immunostained. However, full proof of their intrinsic origin has been given by the use of separate cultures of the two main plexi, which give rise to numerous peptide-containing nerve fibres (Jessen el al., 1979 ). An intense vasoactive intestinal polypeptide innervation is also found in the salivary glands, pancreas, genito-urinary tract and neurohypophysis.
( intestinal polypeptide, enkephalin(s), somatostatin, neurotensin, substance P, gastrin/CCK and bombesin. polypeptide are found in the circulation and the tumour (pancreatic or neural) (Bloom & Polak, 1975) .
(ii) Non-tumour pathology. A significant decrease in vasoactive intestinal polypeptide from 236 43 pmol/g (controls) to 75 22pmol/g wet wt. (means s.D.; P < 0.005) has recently been found in the gut in Chagas' disease (Polak et al., 1979) . Vasoactive intestinal polypeptide nerves are markedly decreased in the areas of severe ganglionitis and aganglionosis which are characteristic of this disease. Similar findings have also been noted in Hirschprung's disease, another bowel disease consisting of severe segmental colonic aganglionosis (Polak et al., 1979) .
Conversely, in the inflammatory bowel condition of Crohn's disease, a significant (P < 0.05) increase in vasoactive intestinal polypeptide content (252 k49pmol/g wet wt.; controls 12 1 f 9 pmol/g) and immunostained nerves is frequently found (Polak ef al., 1978a). Substance P. Substance P is an 1 1-amino acid peptide found not only in the gut and brain, but also in many areas of sensory transmission such as skin, genito-urinary tract and lung (Skrabanek & Powell, 1977) . It is principally present in the autonomic innervation. In the gut its distribution and its system of intrinsic cell bodies parallels closely that of vasoactive intestinal polypeptide.
(a) Pathology. A significant decrease in substance P fibres has also been noted in both Chagas' and Hirschprung's disease (Polak et al., 1979) .
Somatostatin. Somatostatin is a 14-amino acid peptide found principally in the brain and the D-cells of the gut and pancreas. It is a powerful inhibitor not only of all the gut hormones, but also of many gastrointestinal functions .
(a) Pathology. Tumours of the pancreas often produce somatostatin, either alone or combined with other hormones . -It has recently been suggested that somatostatin deficiency may be a pathogenic factor in two separate diseases: duodenal ulceration (Chayvialle et al. , 1978) and neonatal hypoglycaemia with hyperinsulinism (Polak & Bloom, 19796) Enkephalins. [Methioninel-and [leucinel- enkephalins are pentapeptides which differ by only one amino acid residue at the C-terminal. [Methioninelenkephalin forms part of a larger group of peptides known as endorphins (ENDOgenous moRPHINE) (Guillemin, 1978) . The enkephalins, in an approximate methionineheucine ratio of 4, are found in the gut, mainly in the innervation, in the brain and in some sympathetic tissue, including the carotid body (Polak & Bloom, 1979~) .
Bombesin. This is a 14-amino acid peptide originally extracted from the discoglossid frog Bombina bombina (Erspamer & Melchiorri, 1973) .
Bombesin is present mostly in brain, gut and lung. In the gut, Vol. 8 immunocytochemistry localizes it to nerves (man and other mammals) and cells (birds), but exclusively to endocrine cells in the lung (human and other mammals) (Polak et al., 19786) .
Conclusions
Nervous versus hormonal control of the gut. Pavlov's original concept of neural control of the gut was swept away by the revolutionary idea of 'chemical (hormonal) messengers' put forward by Bayliss & Starling (1902) . These two apparently opposing views are now reconciled by the findings of identical regulatory peptides in both the endocrine and neural components of the gut.
The autonomic nervous system of the gut. In 1899 Dogie1 challenged Langley's (1898) bipartite division of the autonomic nervous system, by describing a third type of neuron in the myenteric plexus of the gut. Seventy one years later, Baumgarten et al. ( 1970) convincingly showed at the electron-microscopical level a third type of neuron containing large electron-dense secretory granules (P-type) quite distinct from the small adrenergic or cholinergic granules. The complexity and variety of the autonomic nerve fibres was later emphasized by Cooke & Burnstock (1976) . The finding of at least four neuropeptides vasoactive intestinal polypeptide, substance P, enkephalins and bombesin) in the autonomic innervation further underlines the existence of an important non-cholinergic non-adrenergic, possibly peptidergic, component of the system.
In addition, the discovery of this peptidergic component suggests an explanation for the number of atropin-resistant neurally mediated gut responses such as gastric relaxation and intestinal vasodilation which can now be mimicked by small amounts of some of these neuropeptides, injected into the local circulation (Fahrenkrug et al., 1978) . High concentrations of peptides (e.g. vasoactive intestinal polypeptide) are also found in the local nervous drainage after nerve stimulation.
Common embryological origin. Pearse's prophecy (1969) that the diffuse endocrine system would be found to be merely an embryonic outpouch of the brain has been largely fulfilled by the finding of identical peptides in both the brain and gut.
Gastrointestinal physiology and pathology. Gastrointestinal functions are controlled by numerous factors including the gastrointestinal hormones and the neuropeptides. We now know the distribution and site of origin of these peptides in the gut. We also know of their powerful influence on a number of gut functions (e.g. motility, secretion) in health and disease. Further investigation of their actions and interactions will lead to a better understanding of gut physiology and pathology., The gastrointestinal (GI) hormones have provided a fruitful field for investigation by chemists, physiologists and pharmacologists, but for clinicians who had hoped to find in them the answer to many of the world's ills they have so far proved a disappointment. None of the gastrointestinal hormones that have been characterized to date has emerged as a major cause of illness and many have still to be demonstrated to be associated, let alone causally involved, with any disease process at all.
Functional diseases of the traditional compact ductless glands are generally associated with either over-or under-secretion of their hormonal products. These, in turn, are responsible for producing well-defined clinical syndromes amenable to correction either by extirpation of the gland or replacement by exogenous hormone.
Elucidation of the clinical consequences of conventional endocrine disease has been facilitated by the relative ease with which discrete organs, such as thyroid, suprarenal, pituitary and parathyroid glands, can be removed surgically, their secretory products isolated and characterized, and made available for replacement therapy. Moreover, since spontaneously occurring functional disorders of the ductless glands are almost invariably associated with naked eye, let alone microscopical, lesions they are usually easily identified. Virtually none of these advantages are available to the clinical student of the gastrointestinal hormones which are, with few exceptions, the products of diffusely scattered cells whose identification, let alone quantification, presents almost insuperable difficulties to investigators without access to immuno-histological and electron-microscopy facilities.
Clear, incontrovertible and potentially remedial involvement of GI hormones in the pathogenesis of disease is limited, at the present time, to a few diseases, each of them individually exceedingly rare, and whose presence is indicated usually, if not invariably, by anatomically recognizable abnormalities of the gastrointestinal endocrine cells, usually in the pancreas but also, very occasionally, in the alimentary tract itself. Most of these lesions behave as malignant tumours, though a minority, mainly insulinomas, are benign or rarely non-neoplastic.
Other diseases have been postulated, on the basis of their known pharmacological actions, to be due to functional abnormalities of GI hormone secretion, without associated anatomical abnormalities, but evidence of this is almost entirely lacking.
At the present time there is little reason to believe, beyond conjecture, that deficiency of any single GI hormone, except insulin, is responsible for disease in man or experimental animals.
Production of hormonal deficiency by ablation of its cells of origin is impossible in the case of GI hormones without producing such gross interference with other hormones, let alone nutrition, as to make interpretation impossible. The greatest hope for elucidation of the consequences of hormone deletion rests therefore on: (1) the ability to produce selective, and necessarily short-term, hormone deficiency by passive immunization; (2) the fortuitous discovery of selective endocrine cell poisons analogous to alloxan for the B-cells of the pancreas; (3) 'experiments of nature', i.e. spontaneously occurring diseases, in which one type of endocrine cell only is affected.
The diseases in man that can be attributed to abnormalities of GI hormone secretion are: (1) diabetes, due to insulin deficiency and/or defective B-cell function; (2) hyperinsulinism, perhaps more aptly termed dysinsulinism, due to insulinomas; and the (3) Zollinger-Ellison, (4) glucagonoma, ( 5 ) Verner-Morrison, (6) carcinoidosis and, possibly, (7) somatostatinoma syndromes, though, apart from the Zollinger-Ellison syndrome, which is due to excessive and inappropriate gastrin secretion, the aetiological agents responsible for the other syndromes are not known for certainty. They may not be the same in every case of
